Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms

Standard

Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. / Tögel, Florian; Hu, Zhuma; Weiss, Kathleen; Isaac, Jorge; Lange, Claudia; Westenfelder, Christof.

In: AM J PHYSIOL-RENAL, Vol. 289, No. 1, 01.07.2005, p. F31-42.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{3a09fd29679742c4a6cdfa437a111d0b,
title = "Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms",
abstract = "Severe acute renal failure (ARF) remains a common, largely treatment-resistant clinical problem with disturbingly high mortality rates. Therefore, we tested whether administration of multipotent mesenchymal stem cells (MSC) to anesthetized rats with ischemia-reperfusion-induced ARF (40-min bilateral renal pedicle clamping) could improve the outcome through amelioration of inflammatory, vascular, and apoptotic/necrotic manifestations of ischemic kidney injury. Accordingly, intracarotid administration of MSC (approximately 10(6)/animal) either immediately or 24 h after renal ischemia resulted in significantly improved renal function, higher proliferative and lower apoptotic indexes, as well as lower renal injury and unchanged leukocyte infiltration scores. Such renoprotection was not obtained with syngeneic fibroblasts. Using in vivo two-photon laser confocal microscopy, fluorescence-labeled MSC were detected early after injection in glomeruli, and low numbers attached at microvasculature sites. However, within 3 days of administration, none of the administered MSC had differentiated into a tubular or endothelial cell phenotype. At 24 h after injury, expression of proinflammatory cytokines IL-1beta, TNF-alpha, IFN-gamma, and inducible nitric oxide synthase was significantly reduced and that of anti-inflammatory IL-10 and bFGF, TGF-alpha, and Bcl-2 was highly upregulated in treated kidneys. We conclude that the early, highly significant renoprotection obtained with MSC is of considerable therapeutic promise for the cell-based management of clinical ARF. The beneficial effects of MSC are primarily mediated via complex paracrine actions and not by their differentiation into target cells, which, as such, appears to be a more protracted response that may become important in late-stage organ repair.",
keywords = "Acute Kidney Injury, Animals, Bone Marrow Cells, Cell Differentiation, Fibroblasts, Gene Expression Regulation, Kidney, Male, Mesenchymal Stem Cell Transplantation, Mesenchymal Stromal Cells, Rats, Rats, Inbred F344, Rats, Sprague-Dawley, Reperfusion Injury",
author = "Florian T{\"o}gel and Zhuma Hu and Kathleen Weiss and Jorge Isaac and Claudia Lange and Christof Westenfelder",
year = "2005",
month = jul,
day = "1",
doi = "10.1152/ajprenal.00007.2005",
language = "English",
volume = "289",
pages = "F31--42",
journal = "AM J PHYSIOL-RENAL",
issn = "1931-857X",
publisher = "AMER PHYSIOLOGICAL SOC",
number = "1",

}

RIS

TY - JOUR

T1 - Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms

AU - Tögel, Florian

AU - Hu, Zhuma

AU - Weiss, Kathleen

AU - Isaac, Jorge

AU - Lange, Claudia

AU - Westenfelder, Christof

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Severe acute renal failure (ARF) remains a common, largely treatment-resistant clinical problem with disturbingly high mortality rates. Therefore, we tested whether administration of multipotent mesenchymal stem cells (MSC) to anesthetized rats with ischemia-reperfusion-induced ARF (40-min bilateral renal pedicle clamping) could improve the outcome through amelioration of inflammatory, vascular, and apoptotic/necrotic manifestations of ischemic kidney injury. Accordingly, intracarotid administration of MSC (approximately 10(6)/animal) either immediately or 24 h after renal ischemia resulted in significantly improved renal function, higher proliferative and lower apoptotic indexes, as well as lower renal injury and unchanged leukocyte infiltration scores. Such renoprotection was not obtained with syngeneic fibroblasts. Using in vivo two-photon laser confocal microscopy, fluorescence-labeled MSC were detected early after injection in glomeruli, and low numbers attached at microvasculature sites. However, within 3 days of administration, none of the administered MSC had differentiated into a tubular or endothelial cell phenotype. At 24 h after injury, expression of proinflammatory cytokines IL-1beta, TNF-alpha, IFN-gamma, and inducible nitric oxide synthase was significantly reduced and that of anti-inflammatory IL-10 and bFGF, TGF-alpha, and Bcl-2 was highly upregulated in treated kidneys. We conclude that the early, highly significant renoprotection obtained with MSC is of considerable therapeutic promise for the cell-based management of clinical ARF. The beneficial effects of MSC are primarily mediated via complex paracrine actions and not by their differentiation into target cells, which, as such, appears to be a more protracted response that may become important in late-stage organ repair.

AB - Severe acute renal failure (ARF) remains a common, largely treatment-resistant clinical problem with disturbingly high mortality rates. Therefore, we tested whether administration of multipotent mesenchymal stem cells (MSC) to anesthetized rats with ischemia-reperfusion-induced ARF (40-min bilateral renal pedicle clamping) could improve the outcome through amelioration of inflammatory, vascular, and apoptotic/necrotic manifestations of ischemic kidney injury. Accordingly, intracarotid administration of MSC (approximately 10(6)/animal) either immediately or 24 h after renal ischemia resulted in significantly improved renal function, higher proliferative and lower apoptotic indexes, as well as lower renal injury and unchanged leukocyte infiltration scores. Such renoprotection was not obtained with syngeneic fibroblasts. Using in vivo two-photon laser confocal microscopy, fluorescence-labeled MSC were detected early after injection in glomeruli, and low numbers attached at microvasculature sites. However, within 3 days of administration, none of the administered MSC had differentiated into a tubular or endothelial cell phenotype. At 24 h after injury, expression of proinflammatory cytokines IL-1beta, TNF-alpha, IFN-gamma, and inducible nitric oxide synthase was significantly reduced and that of anti-inflammatory IL-10 and bFGF, TGF-alpha, and Bcl-2 was highly upregulated in treated kidneys. We conclude that the early, highly significant renoprotection obtained with MSC is of considerable therapeutic promise for the cell-based management of clinical ARF. The beneficial effects of MSC are primarily mediated via complex paracrine actions and not by their differentiation into target cells, which, as such, appears to be a more protracted response that may become important in late-stage organ repair.

KW - Acute Kidney Injury

KW - Animals

KW - Bone Marrow Cells

KW - Cell Differentiation

KW - Fibroblasts

KW - Gene Expression Regulation

KW - Kidney

KW - Male

KW - Mesenchymal Stem Cell Transplantation

KW - Mesenchymal Stromal Cells

KW - Rats

KW - Rats, Inbred F344

KW - Rats, Sprague-Dawley

KW - Reperfusion Injury

U2 - 10.1152/ajprenal.00007.2005

DO - 10.1152/ajprenal.00007.2005

M3 - SCORING: Journal article

C2 - 15713913

VL - 289

SP - F31-42

JO - AM J PHYSIOL-RENAL

JF - AM J PHYSIOL-RENAL

SN - 1931-857X

IS - 1

ER -